Could cause temporary or reversible harm; serious harm is unlikely.
cGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits.
| Brand name | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE |
| Generic name | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | BISOPROLOL FUMARATE, HYDROCHLOROTHIAZIDE |
| Distributed by / for | UNICHEM PHARMACEUTICALS (USA), INC., East Brunswick, NJ 08816 |
| NDC | 29300-187-01 |
| Full product label | Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg, 100-count bottle, Rx Only, Manufactured by: UNICHEM LABORATORIS LTD., Pilerne Ind. Estate, Pilerne, Bardez, Goa 403 511, India, Manufactured for: UNICHEM PHARMACEUTICALS (USA), INC., East Brunswick, NJ 08816, NDC 29300-187-01 |
| Recalling firm | Unichem Pharmaceuticals USA Inc. |
| Distribution | US Nationwide and PR. |
| Quantity | N/A |
| Recall initiated | 2026-01-21 |
| Report date | 2026-02-11 |
| Recall completed | — |
| Recall number | D-0301-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | East Brunswick NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗